Tags : Severe Hemoglobinopathies

CRISPR Therapeutics and Vertex Report Results of CTX001 from First

Shots: The two P-I/ II studies, CLIMB-Thal-111 & CLIMB-SCD-121 studies will assess CTX001 in patients with transfusion-dependent beta-thalassemia & sickle cell disease aged 18-35yrs. and enrolls up to 45 patients with a follow up of ~2yrs. after infusion at six clinical sites       respectively The studies demonstrated a total hemoglobin level of 11.9 g/dL & […]Read More